Eledon announced the FDA granted Orphan Drug designation to tegoprubart for prevention of allograft rejection in liver transplantation. Orphan status can provide up to 7 years of US market exclusivity and other development incentives (tax credits, fee waivers), modestly increasing the asset's commercial value and serving as a near-term positive catalyst for the stock.
Eledon announced the FDA granted Orphan Drug designation to tegoprubart for prevention of allograft rejection in liver transplantation. Orphan status can provide up to 7 years of US market exclusivity and other development incentives (tax credits, fee waivers), modestly increasing the asset's commercial value and serving as a near-term positive catalyst for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
